Applied Story

Are Applied DNA (NASDAQ:APDN) conflicting forward indicators contributing to the latest slide?
Typically, a company's financial statements are the reports that show the financial position of the company. There are three main documents that fall into the category of financial statements. These documents include Applied DNA income statement, its balance sheet, and the statement of cash flows. Potential Applied DNA investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although Applied DNA investors may use each financial statement separately, they are all related. The changes in Applied DNA's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Applied DNA's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages. The goal of Applied DNA fundamental analysis is to do accurate financial forecasts. There are several possible objectives to fundamental analysis, such as projecting of Applied DNA performance into the future periods or doing a reasonable stock valuation. The intrinsic value of Applied DNA shares is the value that is considered the true value of the share. If the intrinsic value Applied is higher than its market price, buying is generally recommended. If it is equal to the market price, it is recommended to hold; and if it is less than the market price, then one should sell all shares Applied DNA. Please read more on our fundamental analysis page.

Are Applied DNA Earnings Expected to grow?

The future earnings power of Applied DNA involves the interaction of many company-specific, industry, and economic forces. Earnings estimates embody investors' opinions of Applied DNA factors such as sales growth, product demand, competitive industry environment, profit margins, and cost controls. Applied DNA stock prices adjust as these expectations change or are proven wrong. The main thing to remember is that equities with high expected earnings growth tend to underperform the market because it is usually difficult to meet the market's high expectations. Companies with low earnings expectations tend to do better than expected. Please use our latest analysis of Applied expected earnings.

How Applied utilizes its cash?

To perform a cash flow analysis of Applied DNA, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Applied DNA is receiving and how much cash it distributes out in a given period. The Applied DNA cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities. Applied DNA Net Cash Flow from Operations is quite stable at the moment as compared to the past year. The company's current value of Net Cash Flow from Operations is estimated at (10.82 Million)

Applied DNA Gross Profit

Applied DNA Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing Applied DNA previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show Applied DNA Gross Profit growth over the last 10 years. Please check Gross Profit in more details.

Acquisition by James Hayward of 80000 shares of Applied DNA subject to Rule 16b-3

Legal trades by Applied DNA insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:

Applied insider trading alert for grant of stock option (right to buy) by James Hayward, Chairman CEO and President, on 7th of January 2021. This event was filed by Applied Dna Sciences Inc with SEC on 2021-01-07. Statement of changes in beneficial ownership - SEC Form 4. James Hayward currently serves as chairman of the board and presidentident, ceo of Applied DNA Sciences [view details]

Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

Breaking down the case for Applied DNA

About Contributor